Fintech PR
Oxford Royale Academy Announces Third-time Win of Prestigious Queen’s Award
Reading Time: 3 minutes
Leading provider of academic summer schools for international students, Oxford Royale Academy (ORA), has today been named as a winner of the Queen’s Award for Enterprise, for the third time in seven years. The Queen’s Award is the highest official accolade for British business, which is granted for exceptional contributions to international trade, innovation or sustainable development. ORA were selected as winners in the international trade category.
“To receive the Queen’s Award three times since 2012 is a tremendous achievement,” said ORA’s Chief Executive and Founder, William Humphreys. “We have been on a very exciting journey since the organisation started 15 years ago, and have welcomed over 20,000 students from more than 160 nations to the United Kingdom to study. I am very proud of the opportunities we offer our students, and the way in which they use these opportunities to succeed in their chosen paths in life. I am also extremely proud of the team at ORA, who work tirelessly to ensure that we deliver an unparalleled cultural and educational experience to every one of our students.”
In order to carve a truly strong and successful path in a highly competitive world, ORA believe that young people now need greater global awareness, more varied cultural experiences, broader global networks, and vitally, personal guidance and direction. And ORA’s summer schools offer exactly this. Students can choose from over 150 courses, all designed to help them gain confidence, experience and a competitive edge. Depending on the course they select, they can experience life in an Oxford University college, visit some of the most heritage-rich locations in the United Kingdom, taste a degree in medicine, build a kit-car or explore AI and blockchain, whilst always working with peers from around the globe.
William continues, “Many young people are capable of exceptional academic, personal and commercial success, but they are simply not aware of opportunities which may be available to them. By offering young people a taste of elite higher education, multi-cultural experiences and innovative subject matter, we can help them to identify their strengths, passions and ambitions. And often, they will grasp new opportunities, which they would never have believed that they could access or achieve. I can personally attest to the value of this approach as we take enormous pride in the success of our students, many of whom have gone on to study at some of the UK’s top universities, such as Oxford and Cambridge Universities and Imperial College, London – and have subsequently made tremendous contributions to British industry and research.”
ORA also firmly believes that the UK must continue to attract more global talent for the benefit of both foreign and British students – and to ensure that the UK continues to lead the world in fields such as research, technology, education and commerce. A recent publication of a report by the UK’s All-Party Parliamentary Group for International Students called for more to be done to encourage international students to study in the UK. This was further endorsed by a recent announcement by International Trade Secretary, Liam Fox and Education Secretary, Damian Hinds, outlining the Government’s ambition to increase the number of international students choosing to complete higher education in the UK by 30%, to 600,000 per annum by 2030.
William says, “We absolutely endorse the findings of the All-Party Parliamentary Group’s report and the ambitions outlined by Liam Fox and Damian Hinds. Incoming international students undoubtedly benefit the UK economically, culturally and socially. By opening the door to more international students, we are excited to be playing a part in ensuring that the UK continues to remain at the forefront of commerce, research and education.”
The Oxbridge experience, together with the breadth of courses and outstanding teaching, has helped ORA to achieve tremendous growth over the past few years, with diverse courses now offered from the heritage-rich British education pinnacles of Cambridge and Oxford, to the US academic powerhouse of Yale. To support this growth, ORA have recently acquired the remarkable Yarnton Manor in Oxford, a 17th Century manor house estate, once owned by the ancestors of Princess Diana, which now acts as an education centre and the company’s HQ. For a company which has seen such tremendous growth and achieved such recognition, this is surely yet another sign that ORA are only just beginning their next chapter, as they continue to challenge traditional approaches to education, build international relations and contribute ever-more exceptional talent and experience to the world of international trade & research.
SOURCE Oxford Royale Academy
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News7 days ago
DEMAND AT ASIAN FACTORIES RISES AT STRONGEST RATE IN OVER 2 YEARS, IMPROVING NEAR-TERM GROWTH OUTLOOK FOR MANUFACTURING WORLDWIDE: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
-
Latest News6 days ago
“The Hainan FTP and Me”: Looking at Hainan’s Transformations
-
Latest News7 days ago
Spendesk combines procurement with spend management through Okko acquisition
-
Latest News4 days ago
Millions of people unite around doing good on the 18th International Good Deeds Day held yesterday worldwide
-
Latest News7 days ago
IMC Pan Asia Alliance Is Now Known as Tsao Pao Chee Group
-
Latest News5 days ago
BII and FMO back BECIS with joint US$50 million financing facility supporting commercial and industrial renewables sector in South-East Asia
-
Latest News4 days ago
Banxso Acquires Australian ASIC License, Enhancing Its Global Trading Operations
-
Latest News7 days ago
Sopra Steria establishes itself in Canada